Premium
Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin
Author(s) -
Icli Fikri,
Karaoguz Handan,
Dincol Dilek,
Gunel Nazan,
Demirkazik Ahmet
Publication year - 1991
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930480312
Subject(s) - medicine , dacarbazine , melanoma , cisplatin , chemotherapy , oncology , metastatic melanoma , surgery , cancer research
Twenty consecutive patients with metastatic malignant melanoma were treated with a combination of 24 hours continuous infusion of dacarbazine (250 mg/m 2 ) and cisplatin (20 mg/m 2 ) for 5 days every 3 weeks. One patient (5%) achieved a complete response (CR) and 3 patients (15%) obtained a partial response (PR) with an overall response rate of 20%. Minimal response was observed in 5 other patients (25%). Complete response duration was 8 months. Median response duration of partial responders was 7 months. Median survival of all responders (CR+PR) was 8.5 months. Toxicity was mild to moderate.